Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774087 | 0.91 | CNR1 (0.36) | FAAHNR1H2NR1H3CNR1HDAC8 | |
| SCHEMBL5776662 | 0.87 | TRPV1 (0.37) | TRPV1HDAC1HDAC2HDAC8 | |
| SCHEMBL5775561 | 0.85 | FAAH (0.39) | FAAHTRPV1HDAC1HDAC2HDAC8 | |
| SCHEMBL5774056 | 0.83 | TRPV1 (0.38) | FAAHTRPV1HDAC1HDAC2HDAC8 | |
| Trifluoroacetic Acid SCHEMBL5772750 | 0.82 | MAPT (0.40) | FAAHCNR1TRPV1 | |
| SCHEMBL5771107 | 0.82 | HDAC4 (0.35) | TRPV1HDAC1HDAC2HDAC8PPARA | |
| SCHEMBL5775722 | 0.82 | GSK3B (0.41) | FAAHTRPV1HDAC1HDAC2HDAC8 | |
| SCHEMBL5776379 | 0.81 | MAPT (0.41) | TRPV1POLQ | |
| SCHEMBL5774573 | 0.80 | LMNA (0.40) | FAAHNR1H2NR1H3TRPV1HDAC1 | |
| SCHEMBL5773874 | 0.80 | MAPT (0.42) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | FAAH 2848/4885NR1H2 51/4885NR1H3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.